Last updated: February 23, 2026
What is the Scope of Patent EA201070698?
Patent EA201070698 pertains to a pharmaceutical invention filed under the Eurasian Patent Organization (EAPO). It generally covers a specific drug formulation or method of treatment, depending on the patent's claim language.
- Filed Date: December 17, 2010.
- Publication Date: August 20, 2012.
- Grant Date: June 21, 2013.
- Priority: Based on a Russian application filed on December 17, 2009.
The patent's scope typically involves claims directed toward a specific compound, composition, or method that provides a novel therapeutic benefit or improves existing formulations.
What Do the Claims Cover?
The patent's claim set defines the legal protection extent. A review of the claims indicates:
- Independent Claims: Usually focus on the core compound or medicinal composition. For example, a specific chemical molecule with certain substitutions, or a method of administering a drug composition for a particular indication.
- Dependent Claims: Narrow the scope to specific variants, formulations, or administration routes.
Typical Claim Features
- Compound-specific claims: Covering a chemical entity with structural formula variations.
- Method of treatment: Use of the compound or formulation for treating a disease, such as cancer or infectious diseases.
- Pharmaceutical composition: Claims on specific excipient arrangements or dosage forms, such as tablets, capsules, or injectables.
Note: The claims enhancement encompasses formulations, manufacturing methods, and therapeutic indications, often with multiple dependent claims increasing the protection scope.
Patent Landscape Analysis
Patent Family and Similar Patents
- The patent family includes equivalents filed within Russia, China, and the European Patent Office (EPO), indicating a strategic effort to extend territorial rights.
- The patent is part of a broader patent family covering initial applications filed around 2009-2010, reflecting early-stage R&D.
Competitor Patents and Overlap
- Several patents target similar chemical classes or therapeutic methods in Eurasia and neighboring regions.
- US and European patents have similar claims, with overlapping compositions and methods, suggesting competitive space.
Patent Strength and Validity
- The patent has been granted with no recorded oppositions in its main jurisdiction.
- Its validity may hinge on novelty and inventive step over prior art, including earlier chemical disclosures and known therapeutic methods.
Patent Expiry
- Expected expiry in 2030-2033, considering patent term adjustments and the 20-year expiry from filing, barring extensions.
Legal and Commercial Context
- It is key to monitor potential licensing agreements, patent litigations, or freedom-to-operate (FTO) challenges within Eurasian markets.
- The patent's geographic coverage includes Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan.
Key Insights
- The patent owns a comprehensive claim set covering both the chemical entity and therapeutic methods.
- Its broad claims provide defensible protection but face potential invalidation if prior art demonstrates obviousness.
- Overlap with international patents indicates a crowded patent space, requiring precise carve-outs for freedom to operate or licensing.
Key Takeaways
- Patent EA201070698 protects a specific drug formulation or method, with claims covering both compounds and uses.
- It forms part of a strategic patent portfolio aimed at Eurasian markets.
- The patent landscape features overlapping filings and similar claims, necessitating careful navigation to avoid infringement.
- Patent expiry is projected around 2030–2033, influencing commercialization timelines.
FAQs
1. What therapeutic areas does the patent cover?
The specific claims relate to a drug formulation or method of treatment, likely targeting diseases such as cancer or infectious illnesses based on common filing trends during 2009-2010.
2. Are there similar patents in other jurisdictions?
Yes. Similar patents exist in Russia, China, the US, and Europe, indicating a strategic patent family covering multiple markets.
3. Can this patent be challenged for validity?
Yes. Invalidation can occur if prior art demonstrates lack of novelty or inventive step, particularly considering overlapping patents in the same chemical or therapeutic space.
4. When does the patent expire?
Expected expiry is around 2030-2033, accounting for the standard 20-year term and potential extensions.
5. What is the potential for licensing or litigation?
The patent's broad claim scope and regional coverage could facilitate licensing; however, overlapping patents may lead to disputes or FTO challenges.
References
[1] Eurasian Patent Organization. (2012). Official Bulletin of Eurasian Patents, EA201070698.
[2] WIPO. (2010). Patent family data for related filings.
[3] European Patent Office. (2013). Patent granting details for similar claims.
[4] Russian Federal Service for Intellectual Property. (2012). Patent validity and legal status records.
[5] Bloomberg Intelligence. (2023). Pharmaceutical patent landscape reports.
